R&D | January 14, 2026
Zealand Pharma taps Denmark’s supercomputer to supercharge drug discovery
Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs
Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs
he company will focus on production of any pharmaceutical and biotechnological products
The investment will establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to assembly and packaging, with the vast majority being invested in API capacity
Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies
This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo to patients in France, Denmark, Iceland, Sweden, Finland and Norway
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
Winlevi is authorized in EU for the treatment of acne vulgaris
Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
Subscribe To Our Newsletter & Stay Updated
